Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP) recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

A new agreement simplifies the licensing arrangement by providing for the direct licensing with the Traxyz, LLC, the original developer of the technology. This technology has already received 510K clearance by the FDA. 

It is a low-cost, stand-alone stereotactic image-based system which uses data from a pair of mammograms to enable radiologists to accurately position a localization needle or biopsy tool at the location of suspicious abnormalities in the patient's breast. Revolutions Medical believes that the BBS, preliminary called RevTrack, will offer significant advantages for the localization and biopsy of breast abnormalities. This represents another step in Revolutions Medical's mission statement 'to be committed to continually developing and distributing new products and tools to the medical industry, whether internally or through acquisitions. Its goals are to make health care safer and less expensive by reducing risks and cutting time and expenses.'

The BBS localization needle can be modified to use the Company's proprietary RevVac safety syringe technology. Additionally, one of the patents covering the stabilization technology can be used to further enhance the Company's MRI software tools by providing for a proprietary platform for image fusion between MRI and X-Ray. 

Approximately 4 million diagnostic procedures are performed annually worldwide to evaluate abnormalities detected during mammography screening. Revolutions Medical believes that this technology has the potential to be deployed in the vast majority of more than 50,000 mammography machines that are currently in use worldwide. 15,000 of the machines are in the U.S. 

"Revolutions Medical is committed to bring this new exciting product to the marketplace and I am very pleased to have this agreement concluded at the end of 2010, in accordance with our previous statements.  In the near future, by fusing our RevColor and Rev3D MRI technology with x-ray images, we believe there is a possibility of a multi-modal breast imaging technology, which could dramatically increase the accuracy of the detection of breast cancer," states Ron Wheet, CEO, Revolutions Medical Corporation.